Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Total Current Liabilities (2023 - 2026)

ArriVent BioPharma has reported Total Current Liabilities over the past 4 years, most recently at $25.0 million for Q1 2026.

  • Quarterly results put Total Current Liabilities at $25.0 million for Q1 2026, up 92.97% from a year ago — trailing twelve months through Mar 2026 was $25.0 million (up 92.97% YoY), and the annual figure for FY2025 was $25.9 million, up 50.2%.
  • Total Current Liabilities reached $25.0 million in Q1 2026 per AVBP's latest filing, down from $25.9 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $25.9 million in Q4 2025 and bottomed at $10.0 million in Q1 2024.
  • Median Total Current Liabilities over the past 4 years was $16.2 million (2024), compared with a mean of $17.1 million.
  • The largest annual shift saw Total Current Liabilities rose 29.83% in 2025 before it skyrocketed 92.97% in 2026.
  • Over 4 years, Total Current Liabilities stood at $11.6 million in 2023, then surged by 48.61% to $17.3 million in 2024, then skyrocketed by 50.2% to $25.9 million in 2025, then fell by 3.66% to $25.0 million in 2026.
  • Business Quant data shows Total Current Liabilities for AVBP at $25.0 million in Q1 2026, $25.9 million in Q4 2025, and $21.6 million in Q3 2025.